Hao Zeng

ORCID: 0000-0002-1267-0509
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Prostate Cancer Treatment and Research
  • Prostate Cancer Diagnosis and Treatment
  • Renal cell carcinoma treatment
  • Bladder and Urothelial Cancer Treatments
  • Cancer Genomics and Diagnostics
  • Urologic and reproductive health conditions
  • Cancer Immunotherapy and Biomarkers
  • Cancer, Lipids, and Metabolism
  • Radiopharmaceutical Chemistry and Applications
  • Renal and related cancers
  • Sarcoma Diagnosis and Treatment
  • Multiple and Secondary Primary Cancers
  • Urinary and Genital Oncology Studies
  • Bone Tumor Diagnosis and Treatments
  • Musculoskeletal synovial abnormalities and treatments
  • Ferroptosis and cancer prognosis
  • Advanced Radiotherapy Techniques
  • Cancer, Hypoxia, and Metabolism
  • Radiomics and Machine Learning in Medical Imaging
  • Colorectal Cancer Surgical Treatments
  • Genetic factors in colorectal cancer
  • Cancer Mechanisms and Therapy
  • Pancreatic and Hepatic Oncology Research
  • Lung Cancer Diagnosis and Treatment
  • Urological Disorders and Treatments

Sichuan University
2016-2025

West China Hospital of Sichuan University
2015-2025

Henan Cancer Hospital
2025

Zhengzhou University
2025

Fujian Medical University
2023-2025

First Affiliated Hospital of Fujian Medical University
2025

Nanjing Drum Tower Hospital
2025

Nanjing University of Chinese Medicine
2023-2025

Central South University
2013-2024

Chengdu University
2019-2024

Rationale: This study aimed to use computed tomography (CT) images assess PD-L1 expression in non-small cell lung cancer (NSCLC) and predict response immunotherapy. Methods: We retrospectively analyzed a dataset that consisted of 939 consecutive stage IIIB-IV NSCLC patients with pretreatment CT images. A deep convolutional neural network was trained optimized from the training cohort (n = 750) validation 93) obtain signature (PD-L1ES), which evaluated using test 96). Finally, separate...

10.7150/thno.48027 article EN cc-by Theranostics 2020-12-16

Abstract Purpose: Fumarate hydratase–deficient renal cell carcinoma (FH-deficient RCC) is a rare but lethal subtype of RCC. Little known about the genomic profile FH-deficient RCC, and therapeutic options for advanced disease are limited. To this end, we performed comprehensive genomics study to characterize epigenomic features Experimental Design: Integrated genomic, epigenomic, molecular analyses were on 25 untreated primary RCCs. Complete clinicopathologic follow-up data these patients...

10.1158/1078-0432.ccr-20-3788 article EN Clinical Cancer Research 2021-01-07

Background Cyclic GMP-AMP synthase (cGAS)-stimulator-of-interferon genes (STING) pathway is a cytosolic DNA sensor system. The production of this pathway, interferon-β (IFNβ), could suppress the growth tumor cells, yet it unclear whether ferroptosis involved in IFNβ-induced cell death. Methods effects IFNβ on were analyzed HT1080, 4T1, HCT116 and 786-O cells. HT1080 4T1 cells treated with subjected to RNA-Seq analysis. STAT1, STAT3, TRIM21, TRIM22 silenced by siRNAs examine their...

10.3389/fimmu.2025.1535554 article EN cc-by Frontiers in Immunology 2025-02-05

In clinical practice, the detection of biomarkers is mostly based on primary tumors for its convenience in acquisition. However, immune checkpoints may express differently between and metastatic tumor. Therefore, we aimed to compare differential expressions PD-1, PD-L1 PD-L2 sites renal cell carcinoma (RCC).Patients diagnosed with RCC by resection or fine needle aspiration metastasis were included. Immunohistochemistry (IHC) was applied detect expressions. SPSS 22.0 conduct Chi-square,...

10.1186/s12885-019-5578-4 article EN cc-by BMC Cancer 2019-04-16

BACKGROUND Intraductal carcinoma of prostate (IDC‐P) was usually found to be co‐exist with conventional aggressive adenocarcinoma. The presence IDC‐P considered as an adverse pathological factor, which associated high Gleason score, large volume and accelerated disease progression. However, no any information is available on the diagnosed by needle biopsy in patients metastatic cancer. We investigated incidence prognostic value intraductal initial METHODS included 278 cancer treated between...

10.1002/pros.22906 article EN The Prostate 2014-10-13

Background Intraductal carcinoma of prostate (IDC-P) is always underestimated pathological pattern in cancer and its role still unclear castration resistant (CRPC). This study was conducted to investigate the presence roles IDC-P patients with metastatic CRPC. Methods 45 initially diagnosed then progressed CRPC, were included. All them received twice transperineal biopsies at time initial diagnosis samples retrieved detect IDC-P. PSA doubling (PSADT) considered as a parameter presenting...

10.1002/pros.23005 article EN The Prostate 2015-04-27

Abstract Periodontal bone regeneration is a major challenge in the treatment of periodontitis. Currently main obstacle difficulty restoring regenerative vitality periodontal osteoblast lineages suppressed by inflammation, via conventional treatment. CD301b + macrophages were recently identified as subpopulation that characteristic environment, but their role repair has not been reported. The current study indicates may be constituent component repair, and they are devoted to formation...

10.1038/s41368-023-00225-4 article EN cc-by International Journal of Oral Science 2023-05-17

Abstract Periodontitis is a common chronic inflammatory disease that causes the periodontal bone destruction and may ultimately result in tooth loss. With progression of periodontitis, osteoimmunology microenvironment periodontitis damaged leads to formation pathological alveolar resorption. CD301b + macrophages are specific microenvironment, emerging as vital booster for conducting regeneration. However, key upstream targets their potential mechanism remain elusive. In this study, we...

10.1038/s41368-023-00270-z article EN cc-by International Journal of Oral Science 2024-02-28

Abstract All available surgical treatments for benign prostatic hyperplasia (BPH) have their individual advantages or disadvantages. However, the lack of head-to-head studies comparing different surgeries makes it unavailable to conduct direct analysis. To compare efficacy and safety among lasers transurethral resection prostate (TURP) BPH, randomized controlled trials were searched in MEDLINE, EMBASE, Cochrane library, WHO International Clinical Trial Registration Platform Trial.gov by...

10.1038/srep23503 article EN cc-by Scientific Reports 2016-03-24

Multidisciplinary team (MDT) discussion is a widely used model to manage patients diagnosed with cancer. However, there has been no direct evidence prove its effect on the prognosis of metastatic renal cell carcinoma (mRCC) patients, so this study explored impact MDT mRCC patient survival.The clinical data 269 were retrospectively collected from 2012 2021. The cases grouped into and non-MDT groups, then subgroup analysis was performed according different histology types, as well exploring...

10.2147/jmdh.s393457 article EN cc-by-nc Journal of Multidisciplinary Healthcare 2023-02-01

// Jinge Zhao 1, * , Pengfei Shen Guangxi Sun Ni Chen 2, Jiandong Liu 1 Xin Tang 3 Rui Huang 4 Diming Cai 5 Jing Gong 2 Xingming Zhang Zhibin Xiang Li Qiang Wei Peng Zhenhua Jiyan and Hao Zeng Department of Urology, Institute West China Hospital, Sichuan University, Chengdu, 610041, Pathology, Oncology, Nuclear Medicine, Ultrasound, These authors contributed equally to this work Correspondence to: Zeng, email: cdhx510@foxmail.com Liu, kucaizeng@163.com Keywords: metastatic...

10.18632/oncotarget.19520 article EN Oncotarget 2017-07-24

Aims: This study aimed to compare and evaluate the oncological functional prognosis of two surgical approaches for giant cell tumor bone (GCTB) around knee joint provide worthy suggestion clinical treatment. Patients Methods: included 93 patients, who were divided into extended curettage (EC) group segmental resection (SR) group. Relevant preoperative postoperative data collected, evaluated, complications groups analyzed. Local recurrence was assessed via radiological tests. Functional...

10.3389/fonc.2019.00946 article EN cc-by Frontiers in Oncology 2019-09-24

Objectives To investigate the genetic alterations of patients with prostate cancer (PCa) and without intraductal carcinoma (IDC‐P). Patients Methods We performed targeted sequencing plasma cell‐free DNA on 161 adenocarcinoma (PAC) IDC‐P 84 IDC‐P. Genomic were compared between these two groups. The association patients’ survival outcomes was also explored. Results identified that 29.8% (48/161) 21.4% (18/84) harboured genomic in repair pathways, respectively ( P = 0.210). Pathogenic germline...

10.1111/bju.15530 article EN BJU International 2021-06-29

Heat waves are a significant environmental issue threatening global human health. Extreme temperatures can lead to various heat-related illnesses, with heatstroke being among the most severe. Currently, there no effective treatments mitigate multi-organ damage caused by heatstroke. We found that heat stress activated autophagy. Knockdown of autophagy-related gene 7 (ATG7) or knockout autophagy initiation regulatory genes UNC-51-like activating kinase 1/2 (ULK1/ULK2) increased cell death....

10.1016/j.envint.2025.109285 article EN cc-by-nc Environment International 2025-01-19

78 Background: The depth reduction in prostate-specific antigen (PSA) levels serves as a prognostic indicator for patients with high-risk metastatic hormone-sensitive prostate cancer (mHSPC) undergoing treatment abiraterone. However, the potential impact of duration PSA level on prognosis remains uncertain. Methods: We conducted comprehensive review data from 153 mHSPC first-line abiraterone therapy. group analysis was based alterations during Kaplan-Meier survival curves and Cox...

10.1200/jco.2025.43.5_suppl.78 article EN Journal of Clinical Oncology 2025-02-10

TPS616 Background: Despite substantial advances in therapy over the past 20 years, median progression-free survival (mPFS) for advanced RCC patients treated with first-line tyrosine kinase inhibitors (TKIs) and immune checkpoint (ICIs) remains around months (Motzer RJ et al., NEJM 2021, Choueiri TK 2021). Moreover, subsequent treatments post-first-line progression exhibit inadequate efficacy. A phase Ib/II single-arm trial achieved a high objective response rate (ORR) lenvatinib plus...

10.1200/jco.2025.43.5_suppl.tps616 article EN Journal of Clinical Oncology 2025-02-10
Coming Soon ...